Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...

Add Yahoo as a preferred source to see more of our stories on Google. Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare ...

Scientists at Oregon Health & Science University's Casey Eye Institute and Baylor College of Medicine's Cullen Eye Institute published findings from a two-year Phase I clinical trial in the journal ...

The first study to evaluate both eyes treated with a gene therapy targeting neovascular, or wet, age-related macular degeneration (AMD) has found the treatment as safe and effective in the second eye ...

Preliminary results from the Phase 2 ArMaDa clinical trial indicate a 46% reduction in lesion growth compared to the control group after 12 months, with no serious adverse events reported across both ...

The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, ...

Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by working to bring to market three treatments for blindness-related diseases, two ...

Shares of Krystal Biotech KRYS gained 3.9% yesterday after the company announced that it had dosed the first patient in a phase I/II study evaluating its eye drop KB801 for the treatment of ...

The UC Davis Department of Ophthalmology has received a five-year, $3.6 million grant from the National Eye Institute to explore a new way to treat vision loss using gene therapy. The research could ...

Dr. Glenn Yiu, M.D., Ph.D., is a board-certified vitreoretinal specialist and surgeon at the UC Davis Eye Center. (SACRAMENTO, Calif.) — The UC Davis Department of Ophthalmology has received a ...